← All trials
NCT01899820
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2013
- Primary completion
- Jun 1, 2014
- Completion date
- Jul 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 2100
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- KEMRI-Wellcome Trust Collaborative Research ProgramLead sponsor
- Kenya Medical Research InstituteCollaborator
- Kenya Medical Research InstituteOverall official - principal investigator
- Kenya Medical Research InstituteSponsor investigator
- World BankCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.